Prevention of hearing loss in children receiving cisplatin chemotherapy

Journal of Clinical Oncology

Volumn 27, Issue 2, 2009, Pages 317-318

  Freyer, David R ^a   Sung, Lillian ^a   Reaman, Gregory H ^a  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; CISPLATIN; SODIUM THIOSULFATE;

AUDIOMETRY; CANCER CHEMOTHERAPY; CHILDHOOD CANCER; DRUG MECHANISM; HEARING LOSS; HUMAN; HYPOCALCEMIA; HYPOTENSION; LETTER; NAUSEA; OTOTOXICITY; PRIORITY JOURNAL; VOMITING; CHEMICALLY INDUCED DISORDER; CHILD; MEDULLOBLASTOMA; NOTE;

AMIFOSTINE; CHILD; CISPLATIN; HEARING LOSS; HUMANS; MEDULLOBLASTOMA;

EID: 58249084732     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.1160     Document Type: Letter

References (16)

1. Fouladi M, Chintagumpala M, Ashley D, et al: Amifostine protects against cisplatin-induced ototoxicity in children with average-risk medulloblastoma. J Clin Oncol 26:3749-3755, 2008
2. Marina N, Chang KW, Malogolowkin M, et al: Amifostine does not protect against the ototoxicity of high-dose cisplatin combined with etoposide and bleomycin in pediatric germ cell tumors: A Children's Oncology Group study. Cancer 104:841-847, 2005
3. Fisher MJ, Lange BJ, Needle MN, et al: Amifostine for children with medulloblastoma treated with cisplatin-based chemotherapy. Pediatr Blood Cancer 43:780-784, 2004
4. Katzenstein HM, Chang K, Krailo M, et al: A randomized study of platinum-based chemotherapy with or without amifostine for the treatment of children with hepatoblastoma: A report of the Intergroup Hepatoblastoma Study P9645. Proc Am Soc Clin Oncol 22:799s, 2004 (suppl; abstr 8518)
5. National Cancer Institute: Phase III randomized study of sodium thiosulfate in preventing ototoxicity in young patients receiving cisplatin chemotherapy for newly diagnosed germ cell tumor, hepatoblastoma, medulloblastoma, neuroblastoma, or osteosarcoma. http://www.cancer.gov/search/ ViewClinicalTrials.aspx?cdrid=588655&version=HealthProfessional& protocolsearchid=5079860
6. Knight KRG, Kraemer DR, Neuwelt EA: Ototoxicity in children receiving platinum chemotherapy: Underestimating a commonly occuring toxicity that may influence academic and social development. J Clin Oncol 23:8588-8596, 2005
7. Neuwelt EA, Gilmer-Knight K, Lacy C, et al: Toxicity profile of delayed high-dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain barrier disruption. Pediatr Blood Cancer 47:174-182, 2006
8. Leitao DJ, Blakely BW: Quantification of sodium thiosulphate protection on CDDP-induced toxicities. J Otolaryngol 32:146-150, 2003
9. Muldoon LL, Pagel MA, Kroll RA, et al: Delayed administration of sodium thiosulfate in animal models reduces platinum ototoxicity without reduction of antitumor activity. Clin Cancer Res 6:309-315, 2000
10. Dickey DT, Wu JY, Muldoon LL, et al: Protection against CDDP-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 314:1052-1058, 2005
11. Harned TM, Kalous O, Neuwelt A, et al: Sodium thiosulfate administered six hours after cisplatin does not compromise antineuroblastoma activity. Clin Cancer Res 14:533-540, 2008
12. Neuwelt EA, Brummet RE, Doolittle ND, et al: First evidence of otoprotection against carboplatin-induced hearing loss with a two-compartment system in patients with central nervous system malignancy using sodium thiosulfate. J Pharmacol Exp Ther 286:77-84, 1998
13. Doolittle ND, Muldoon LL, Brummett RE, et al: Delayed sodium thiosulfate as an otoprotectant against carboplatin-induced hearing loss in patients with malignant brain tumors. Clin Cancer Res 7:493-500, 2001
14. Doolittle ND, Tyson RM, Lacy C, et al: Potential role of delayed sodium thiosulfate as protectant against severe carboplatin-induced thrombocytopenia in patients with malignant brain tumors. Blood 98:37a-38a, 2001 (abstr 149)
15. Kumar P, Robbins KT: Treatment of advanced head and neck cancer with intra-arterial CDDP and concurrent radiation therapy: The RADPLAT protocol. Curr Oncol Rep 3:59-65, 2001
16. Robbins KT, Fontanesi J, Wong F, et al: A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx. Arch Otolaryng Head Neck Surg 122:853-857, 1996